Clinical Trial Update: Apixaban for Treatment of Embolic Stroke of Undetermined Source [Phase 3]

View source ↗

Summary

Phase 3 trial update for apixaban in the treatment of embolic stroke of undetermined source has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embolic Stroke of Undetermined Source

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Embolic Stroke of Undetermined Source | Phase 3 | Status: COMPLETED